Genta Incorporated to Host Conference Call to Discuss Third Quarter 2009 Financial Results and Operational Priorities on November 16, 2009

The detailed quantitative results from the Company's Phase 3 trial in advanced melanoma, known as AGENDA, will also be presented on November 16, 2009, at the international conference, "Molecular Targets and Cancer Therapeutics" , in Boston, MA in an oral session at 5:00 PM EST. In the conference call and webcast, the Company expects to discuss current results and to review potential plans for the evaluation of overall survival from AGENDA. As of November 4, 2009, the Company has communicated with its investigators that - based upon the recommendation of the trial's Independent Data Monitoring Board - the double-blind design will remain in place, and all patients are currently expected to continue in the study as originally planned. During the conference call and webcast, the Company also expects to review actions that will restructure operations, conserve cash, and prioritize expenses that will accelerate development of our pipeline products, tesetaxel and oral gallium.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 37594914.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially" , "anticipate" , "could" , "calls for" , and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

• the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies such as the U.S. Food and Drug Administration ("FDA" );
• the safety and efficacy of the Company's products or product candidates;
• the commencement and completion of any clinical trials;
• the Company's assessment of its clinical trials;
• the Company's ability to develop, manufacture, license, or sell its products or product candidates;
• the Company's ability to enter into and successfully execute any license and collaborative agreements;
• the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, the financial ability to sustain further followup in the AGENDA trial, or the Company's risk of bankruptcy;
• the adequacy of the Company's patents and proprietary rights;
• the impact of litigation that has been brought against the Company; and
• the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

Genta Investor Relations
908-286-3980
info@genta.com